阿扑吗啡舌下膜治疗帕金森病关期发作的3期随机对照研究
这项在美国32个中心及加拿大1个中心开展的随机、双盲、安慰剂对照3期研究纳入109例每日关期≥2小时且有可预测晨间关期的帕金森病患者,经开放标签滴定后按1:1随机接受有效剂量阿扑吗啡舌下膜或安慰剂治疗12周。
要点
- 阿扑吗啡舌下膜对帕金森病关期发作有按需治疗效果,第12周运动评分改善优于安慰剂
- 最常见不良事件为轻中度口咽部事件,阿扑吗啡组31%、安慰剂组7%,可导致停药
- 其他常见不良事件为短暂恶心、嗜睡和头晕,直立性低血压等少见
核心结论
- 阿扑吗啡舌下膜为大多数帕金森病患者的关期发作提供了有效的按需治疗,但近三分之一患者主要因口咽部副作用停药。
研究设计与样本
- 随机、双盲、安慰剂对照3期研究,由运动障碍专家在美国32个中心及加拿大1个中心开展。
- 纳入每日关期≥2小时、有可预测晨间关期、对左旋多巴有反应且抗帕金森病药物剂量稳定的帕金森病患者。
- 开放标签滴定阶段给予阿扑吗啡舌下膜10–35 mg递增剂量至可耐受的完全开期反应,随后按1:1随机进入12周双盲维持期。
- 共纳入109例患者,阿扑吗啡组54例、安慰剂组55例;主要终点按改良意向治疗人群分析。
主要发现
- 轻中度口咽部事件:阿扑吗啡组17/54例(31%),安慰剂组4/55例(7%),导致停药分别为9例(17%)和1例(2%)。
- 其他治疗中出现的不良事件包括短暂恶心15例(28%)、嗜睡7例(13%)、头晕5例(9%)。
- 直立性低血压、晕厥、异动症、幻觉、QT间期延长和冲动控制障碍少见(所有患者中患病率≤2%)或未发生;阿扑吗啡组1例有已知心脏危险因素的患者发生致死性心脏骤停。
关键数值与推荐
- 主要终点为第12周临床内给药后30分钟MDS-UPDRS第3部分(运动)评分较给药前的变化。
- 阿扑吗啡舌下膜滴定剂量范围为10–35 mg。
- 阿扑吗啡组54例中34例(63%)完成研究,安慰剂组55例中46例(84%)完成研究。
临床怎么用
- 对于每日关期≥2小时且有可预测晨间关期、对左旋多巴有反应的帕金森病患者,可考虑阿扑吗啡舌下膜作为按需治疗。
- 用药需经开放标签滴定确定有效且可耐受的剂量,并关注口咽部不良反应及停药风险。
- 治疗中需监测恶心、嗜睡、头晕等不良事件,对有心律失常危险因素者应谨慎。
局限性
- 原文未报告研究的具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many patients with Parkinson's disease have potentially disabling off episodes that are not predictably responsive to levodopa. In this study, we assessed the safety and efficacy of apomorphine sublingual film as an on-demand therapy for off episodes in patients with Parkinson's disease. METHODS: This randomised, double-blind, placebo-controlled study was done by movement disorder specialists at 32 sites in the USA and one in Canada. Patients with Parkinson's disease who had 2 h or more of off time per day with predictable morning off periods, were responsive to levodopa, and were on stable doses of anti-parkinsonian medication were eligible. In an open-label titration phase, increasing doses of apomorphine sublingual film (10-35 mg) were administered until a tolerable full on response was achieved. Patients were then randomly assigned (1:1) with an interactive web-response system to receive the effective dose of apomorphine sublingual film or matching placebo in a 12-week, double-blind maintenance phase. Randomisation was not stratified, and the block size was four. All patients and study personnel were masked to treatment assignments. The primary endpoint was the in-clinic change from predose to 30 min post-dose in the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part 3 (motor) score at week 12, analysed on a modified intention-to-treat population by use of a mixed-effect model for repeated measures. Safety analyses were done on all enrolled patients who received at least one dose of study medication. This trial is registered with ClinicalTrials.gov, NCT02469090. FINDINGS: Between June 18, 2015, and Dec 11, 2017, 109 patients were enrolled and randomly assigned to receive apomorphine sublingual film (n=54) or placebo (n=55). All patients received the assigned study treatment, and 34 (63%) of 54 patients receiving apomorphine sublingual film and 46 (84%) of 55 receiving placebo completed the study. Least squares mean (SE) change from predose to 30 min post-dose in MDS-UPDRS part 3 score at week 12 was -11·1 (SE 1·46, 95% CI -14·0 to -8·2) with apomorphine sublingual film and -3·5 (1·29, -6·1 to -0·9) with placebo (difference -7·6, SE 1·96, 95% CI -11·5 to -3·7; p=0·0002). Mild-to-moderate oropharyngeal events were the most common side-effect, reported in 17 (31%) of 54 patients receiving apomorphine sublingual film and in four (7%) of 55 patients receiving placebo, leading to treatment discontinuation in nine (17%) patients treated with apomorphine and in one (2%) patient treated with placebo. Other treatment-emergent adverse events were transient nausea (in 15 [28%] patients receiving apomorphine sublingual film), somnolence (seven [13%]), and dizziness (five [9%]). Orthostatic hypotension, syncope, dyskinesia, hallucinations, prolongation of the QT interval, and impulse control disorders were infrequent (prevalence ≤2% of all patients) or did not occur. One patient treated with apomorphine sublingual film (with known cardiac risk factors) had a fatal cardiac arrest. INTERPRETATION: Although nearly a third of patients discontinued treatment primarily because of oropharyngeal side-effects, apomorphine sublingual film provided an efficacious, on-demand treatment for off episodes for most patients with Parkinson's disease in this trial. The long-term safety and efficacy of apomorphine sublingual film are currently being investigated. FUNDING: Cynapsus Therapeutics and Sunovion.
引用
- Olanow CW, Factor SA, Espay AJ, et al. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2019. PMID: 31818699. doi:10.1016/S1474-4422(19)30396-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。